Please login to the form below

Not currently logged in
Email:
Password:

Zortress

This page shows the latest Zortress news and features for those working in and with pharma, biotech and healthcare.

Jobs to do

Jobs to do

having the potential for the management of Alzheimer's disease, or everolimus (Afinitor/ Zortress, originally developed for organ transplantation) in multiple types of cancer tumour.

Latest news

  • Novartis' Zortress cleared by FDA for liver transplants Novartis' Zortress cleared by FDA for liver transplants

    After the 30-day period, they were randomised to receive Zortress plus reduced-exposure tacrolimus, Zortress followed by tacrolimus withdrawal at four months, or standard-exposure tacrolimus only. ... Zortress/Certican achieved sales of $210m in

  • FDA approves Afinitor for pancreatic cancer

    In the US, everolimus is also available in different dosage strengths under the trade name Zortress for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving

  • FDA clears test for Novartis' Zortress

    The US Food and Drug Administration has cleared a test that monitors blood levels of Novartis' recently approved immunosuppressant Zortress. ... The US Food and Drug Administration (FDA) has cleared a test that monitors blood levels of Novartis'

  • Getting the GIST

    Several mTOR antagonists have already been launched for different cancers and could therefore be prescribed as off-label therapy; these include everolimus (Zortress/Certican, Novartis), sirolimus (Rapamune, Wyeth) and temsirolimus (Torisel,

  • Novartis' net income up 15 per cent for Q2

    Successful launches included Exjade (deferasirox), which made $192m after receiving regulatory approvals in the US and Europe for the treatment of chronic iron overload, and Certican/Zortress (everolimus) which made $26m

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...